Asset 1

Gentest®
Enzyme Inhibition Services

Cytochrome P450 & UGT and oxidase & esterase inhibition studies
to predict drug-drug interaction.

Gentest® ADME Research Services' enzyme inhibition assays are valuable predictors of your drug candidate’s drug-drug interaction potential.

Gentest® has been providing expert, regulatory submission-quality ADME services for more than two decades and offers a range of metabolic enzyme studies beyond the standard seven CYPs. Experienced study directors and the use of Gentest® products, including pooled human liver microsomes (Ultrapool™ HLM150) and cDNA expressed individual enzymes (Supersomes® ) ensure you receive robust, IND submission-ready results.

Testing for Comprehensive Metabolizing Enzymes

Reversible and Time-Dependent Inhibition Testing for Cytochrome P450s

Qualified Incubation Conditions

Robust IND-Enabling Studies

Featured Publications​

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach
facilitates kinact assay design

Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine

Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible

Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model

Contact Us Today

Quick Links

Technologies

Development and Clinical
Trial Solutions